Quick Summary
Novoseven 2mg Injection
Last updated on 26 Sep 2026 | 08:43 AM (IST)
₹88444
MRP: ₹92132.81
(You Save ₹3688.81)
1 VIAL(s)
Novoseven 2mg Injection
Salt Composition
FACTOR VIIMarketer
NOVO NORDISK INDIA PVT LTD
Prepaid Only. Non-Returnable.
4% OFF
₹88444
MRP: ₹92,132.81
Inclusive of all taxes
4% Off
Salt Composition
FACTOR VIIMarketer
NOVO NORDISK INDIA PVT LTD
Prepaid Only. Non-Returnable.
Dispatch: Today
Care delivered without the wait. Your order is prioritized for rapid dispatch to ensure it reaches your doorstep on time.
Introduction to Novoseven 2mg Injection
Novoseven 2mg injection contains active components such as Factor VII. It, also known as coagulation Factor VII or FVII, is a protein involved in the blood clotting (coagulation) cascade. This medication can treat bleeding episodes in hemophilia A or B individuals who have developed inhibitors (antibodies) against Factor VIII or Factor IX. In certain situations, healthcare providers may use it to manage bleeding in patients with coagulation disorders who are undergoing surgery or experiencing trauma. Acquired Novoseven 2mg injection deficiency can occur due to various medical conditions, such as liver disease, vitamin K deficiency, or certain medications. Treatment with this may be considered to address bleeding associated with these conditions. Novoseven 2mg injection has been used experimentally to manage intracranial hemorrhages, particularly in cases of traumatic brain injury or bleeding in the brain.
Patients with a known allergy or hypersensitivity to Novoseven 2mg injection or any of their components should not receive this medication. It is generally not recommended for individuals with DIC, a condition characterized by widespread abnormal blood clotting and bleeding. Patients with a history of thromboembolic events or those at a high risk of developing them should use it cautiously and under close medical supervision. In some cases of intracranial hemorrhage (bleeding within the brain), using It can be contraindicated when there is evidence of inappropriate clot formation, such as in cases of cerebral venous sinus thrombosis. Novoseven 2mg injection concentrates can be used in children with bleeding disorders, but a healthcare provider should closely monitor and prescribe their use. Novoseven 2mg injection concentrates can be used in older adults, but age-related factors, such as other medications, should be considered.
Uses of Novoseven 2mg Injection
Novoseven 2mg injection is used in the following:
- Hemophilia with inhibitors
- Congenital Novoseven 2mg injection deficiency
- Surgery and trauma
- Acquired Novoseven 2mg injection deficiency
- Intracranial hemorrhage
Therapeutic Effects of Novoseven 2mg Injection
Novoseven 2mg injection is a blood clotting protein that plays a pivotal role in coagulation. When tissue damage occurs, it interacts with tissue factor (TF) at the injury site, forming the FVIIa-TF complex. This complex acts as an enzyme, triggering a series of reactions that culminate in thrombin formation and the subsequent creation of a blood clot. This mechanism is essential for stopping bleeding after vascular injury.
Interaction of Novoseven 2mg Injection with other drugs
Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Novoseven 2mg injection, reducing effectiveness by causing undesirable side effects.
More Information about Novoseven 2mg Injection
- Stored at room temperature from 20°C to 25°C.
- Keep away from moisture, heat, and light.
- It should not be frozen.
- Keep away from children and pets.
How to consume Novoseven 2mg Injection
Novoseven 2mg injection concentrates are administered intravenously (IV) to individuals with bleeding disorders. A healthcare provider should determine the specific dosing and administration details based on the patient's condition and needs.
Safety Advice for Novoseven 2mg Injection
Breast Feeding
Novoseven 2mg injection is not usually recommended for breastfeeding mothers because there is limited study on its safety during lactation. It's essential to discuss the risks and benefits of continuing breastfeeding while using this medication with your healthcare provider.
Alcohol
It is generally not safe to take alcohol while taking Novoseven 2mg injection, especially during periods of active bleeding or treatment.
Liver
The use of Novoseven 2mg injection may require caution in individuals with liver conditions. Consult with a healthcare provider for personalized advice if you have liver concerns.
Lungs
If you have lung conditions, consult a doctor before starting Novoseven 2mg injection.
Driving
The use of Novoseven 2mg injection is not typically associated with impaired driving. However, individuals should always follow their healthcare provider's recommendations and monitor their own response to the medication.
Pregnancy
Using Novoseven 2mg injection concentrates during pregnancy should be carefully evaluated by consulting with a healthcare professional.
Side Effects of Novoseven 2mg Injection
Novoseven 2mg injection causes some side effects like all medications, although not everyone will experience them.
Serious
- Thromboembolic events
- Hypersensitivity reactions
- Arterial thrombosis
- Disseminated intravascular coagulation (DIC)
- Hemorrhage
- Hepatic events
- Inhibitor development
Common
- Fever
- Headache
- Nausea and vomiting
- Injection site reactions
Word of Advice
Watch for allergic reactions and the risk of clotting events after taking Novoseven 2mg injection and closely monitoring the medication's dosage and its effects on blood clotting. Special care is needed when using this medication in patients with certain medical conditions like liver problems, kidney issues, heart conditions, or a history of blood clots. Extra attention should be given to children and older adults. It's important to use the medication correctly, store it properly, and educate patients on its use. Emergency plans should be in place for unexpected issues. Also, consider factors like the development of antibodies and genetic variations in patients. Each patient is unique, so there should be communication between the healthcare provider and the patient to achieve the best results.
FAQs about Novoseven 2mg Injection
Q1.
What should I do in an emergency or if I experience adverse effects while using Novoseven 2mg injection?
In emergencies or if you experience severe adverse effects, seek immediate medical attention. Have an emergency plan in place for unexpected issues while using this medication.
Q2.
Can Novoseven 2mg injection be self-administered at home?
Some patients with bleeding disorders may be trained to self-administer Novoseven 2mg injection concentrates at home. However, this depends on individual circumstances and should be supervised by healthcare professionals.
Q3.
Are there any dietary restrictions while using Novoseven 2mg injection?
There are typically no specific dietary restrictions associated with Novoseven 2mg injection concentrates. However, maintaining a balanced diet and staying well-hydrated can support overall health.
Q4.
Is genetic testing necessary before using Novoseven 2mg injection?
In some cases, genetic testing may be considered to identify genetic variations that could impact the patient's response to treatment. However, it is not always required for every patient.
Q5.
Is Novoseven 2mg injection therapy lifelong for individuals with bleeding disorders?
The duration of Novoseven 2mg injection concentrate therapy varies depending on the underlying bleeding disorder and the patient's response to treatment. Some individuals may require lifelong treatment, while others may use it as needed.
Fact Box of Novoseven 2mg Injection
Molecule name: Factor VII | Therapeutic class: Hemostatic Agent |
Pharmacological class: Clotting Factor | Indications: 1. Hemophilia with inhibitors 2. Congenital Novoseven 2mg injection deficiency 3. Surgery and trauma 4. Acquired Novoseven 2mg injection deficiency 5. Intracranial hemorrhage |
References
- Novo Nordisk A/S, Electronic medicines compendium (EMC), [Revised on 13 Jun 2023] [ Accessed on 2nd September 2023], https://www.medicines.org.uk/emc/files/pil.7927.pdf
- LFB S.A. Puteaux, US Food and Drug Administration, [Revised on Dec 2022] [ Accessed on 2nd September 2023],https://www.fda.gov/media/136610/download
- Katherine F Croom, Paul L McCormack; Recombinant Factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders; BioDrugs; Published on 2008; Accessed on 02/09/2023; https://pubmed.ncbi.nlm.nih.gov/18345709/
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Archana Gupta
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 26 Sep 2026 | 08:43 AM (IST)
Want to know more?
Read Our Editorial Policy
